EUVIMEDScopri EUVIMED
Kohortenstudie

The Impact of Utilizing Combined Factor Concentrates for Hemostasis Management in Pediatric Pulmonary Artery Reconstruction: A Propensity Score‐Matched Cohort Study

Kaitlin M Flannery iD, Catherine A Dietrich, Echo V Rowe, Julianne M Mendoza, Sa Shen, Frank L Hanley, Tristan Margetson, Manchula Navaratnam iD

Pediatric Anesthesia · 2026-08 · 36 (8) · 974-982

DOI: 10.1002/pan.70201 ↗

At a glance

Kohortenstudie in Pediatric Anesthesia, published online on 2026-04-24. Written by Kaitlin M Flannery and 7 co-authors. Institution: Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, California, USA. Major MEDLINE topics: Pulmonary Artery, Blood Coagulation Factors, Hemostasis, Plastic Surgery Procedures. Cited 1 times so far (Crossref); 25 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Bleeding after cardiopulmonary bypass in pediatric patients undergoing pulmonary artery reconstruction is a major source of morbidity. Factor concentrates have emerged as off‐label therapy to achieve hemostasis while minimizing transfusion. In 2020, our institution implemented a standardized hemostasis management pathway combining factor concentrates.

Aims

This study evaluates the impact of the pathway on blood product transfusion and thromboembolism for patients undergoing pulmonary artery reconstruction with cardiopulmonary bypass.

Methods

We conducted a retrospective propensity score‐matched cohort study comparing pediatric patients undergoing pulmonary artery reconstruction before and after pathway implementation. The pre‐pathway cohort received activated 4‐factor prothrombin complex concentrate for refractory bleeding with variable dosing, whereas the post‐pathway cohort received both fibrinogen and activated 4‐factor prothrombin complex concentrates in standardized doses. The primary efficacy outcome was total blood product transfused after cardiopulmonary bypass. The primary safety outcome was thromboembolism incidence at seven and 30 days postoperatively. Secondary outcomes included 24‐h chest tube output, time to extubation, length of stay, 30‐day mortality, and acute kidney injury.

Results

A total of 97 pre‐pathway patients and 178 post‐pathway patients were included in the final data set for statistical analysis. After propensity score matching, 87 patients remained in each cohort. The post‐pathway cohort was associated with a statistically significant reduction in total blood products transfused (30.4 mL/kg vs. 47.9 mL/kg, mean difference 17.6 mL/kg, 95% CI [9.82–25.9], p < 0.0001). There was no statistically significant difference in seven‐day (11.5% post‐pathway vs. 8.0% pre‐pathway, OR 1.48, 95% CI 0.51–4.32, p = 0.468) or 30‐day (18.4% post‐pathway vs. 9.2% pre‐pathway, OR 2.23, 95% CI 0.84–5.87, p = 0.106) thromboembolism rates. There were no significant differences in secondary outcomes.

Conclusions

A hemostasis management pathway utilizing combined factor concentrates was associated with significantly reduced post‐bypass transfusion requirements in pediatric pulmonary artery reconstruction. We observed a higher incidence of post‐operative thromboembolism, with a twofold increase at 30 days, although statistical significance was not reached. The majority of post‐operative thromboembolism was associated with indwelling lines. Prospective multicenter studies are needed to validate safety, efficacy and generalizability of utilizing combined factor concentrates in pediatric patients.

Subjects

MeSH terms (MEDLINE)

Pulmonary ArteryBlood Coagulation FactorsHemostasisPlastic Surgery ProceduresPostoperative HemorrhageHumansPropensity ScoreFemaleMaleInfantRetrospective StudiesChild, PreschoolCohort StudiesChildBlood TransfusionCardiopulmonary BypassHemostaticsThromboembolism

Author keywords

coagulationfactor concentratefibrinogenpediatric cardiac surgerypropensity score matchprothrombin complex concentrate

Substances

Blood Coagulation Factorsprothrombin complex concentratesHemostatics

Authors and institutions

  • Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, California, USA.
  • Quantitative Sciences Unit, Stanford University, Stanford, California, USA.
  • Department of Cardiothoracic Surgery, Stanford University, Stanford, California, USA.
  • Department of Cardiovascular Perfusion, Stanford Hospitals and Clinics, Stanford Children's Hospital, Stanford, California, USA.

ORCID profiles: Kaitlin M Flannery, Manchula Navaratnam

Cite

APA

Flannery, K. M., Dietrich, C. A., Rowe, E. V., Mendoza, J. M., Shen, S., Hanley, F. L., Margetson, T., & Navaratnam, M. (2026). The Impact of Utilizing Combined Factor Concentrates for Hemostasis Management in Pediatric Pulmonary Artery Reconstruction: A Propensity Score‐Matched Cohort Study. Pediatric Anesthesia, 36(8), 974-982. https://doi.org/10.1002/pan.70201

Vancouver

Flannery KM, Dietrich CA, Rowe EV, Mendoza JM, Shen S, Hanley FL, et al. The Impact of Utilizing Combined Factor Concentrates for Hemostasis Management in Pediatric Pulmonary Artery Reconstruction: A Propensity Score‐Matched Cohort Study. Pediatric Anesthesia. 2026;36(8):974-982. doi:10.1002/pan.70201

BibTeX
@article{Flannery2026,
  author = {Flannery, Kaitlin M and Dietrich, Catherine A and Rowe, Echo V and Mendoza, Julianne M and Shen, Sa and Hanley, Frank L and Margetson, Tristan and Navaratnam, Manchula},
  title = {The Impact of Utilizing Combined Factor Concentrates for Hemostasis Management in Pediatric Pulmonary Artery Reconstruction: A Propensity Score‐Matched Cohort Study},
  journal = {Pediatric Anesthesia},
  year = {2026},
  volume = {36},
  number = {8},
  pages = {974--982},
  doi = {10.1002/pan.70201}
}
Start for free →